News|Articles|July 6, 2026
Q2 2026 Recap: Psychiatry News & Updates
Author(s)Chelsie Derman
Fact checked by: Tim Smith
Listen
0:00 / 0:00
Key Takeaways
- Lumateperone gained a schizophrenia relapse-prevention indication after a randomized-withdrawal phase 3 trial showed 63% relapse-risk reduction and 84% relapse-free status at 6 months.
- Manufacturing and CMC deficiencies, not clinical findings, drove the FDA’s CRL for once-daily CTx-1301; adult and pediatric phase 3 studies met ADHD-RS-5 and PERMP endpoints.
Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.
Advertisement
Q2 2026 brought regulatory movement, phase 3 data, and structural change to depression care. The
TMS is moving past its 36-session schedule, with accelerated protocols and the at-home device ProlivRx expanding access for treatment-resistant depression, while psychiatrists confront patients turning to AI for mental health support. Here is a look back at the psychiatry drug approvals, phase 3 data, and neuromodulation advances that defined the quarter.
FDA Regulatory Roundup: Schizophrenia, ADHD, and Psychedelic Policy News
FDA Approves Lumateperone sNDA With 63% Relapse Risk Reduction In Schizophrenia
The FDA approved a supplemental New Drug Application (NDA) for lumateperone (Caplyta, Johnson & Johnson), expanding the label to include relapse prevention in schizophrenia. The approval, announced April 27, 2026, was based on phase 3 Study 304, a randomized withdrawal trial showing a 63% reduction in relapse risk versus placebo over 26 weeks, with 84% of patients remaining relapse-free at 6 months. Christoph U. Correll, MD, of the Zucker School of Medicine at Hofstra/Northwell, noted in a press release that relapse often undoes treatment progress and raises hospitalization risk. Lumateperone is already approved for schizophrenia, bipolar depression, and adjunctive MDD.
FDA Issues CRL for CTx-1301 in ADHD Over Manufacturing Concerns
The FDA issued a complete response letter for CTx-1301 (dexmethylphenidate HCl), Cingulate's investigational once-daily ADHD treatment, on June 2, 2026, citing chemistry, manufacturing, and controls concerns rather than clinical safety or efficacy issues. CTx-1301 uses a multi-core, precision timed-release tablet delivering three timed doses over 12 to 16 hours. Pivotal phase 3 trials in adults and in children and adolescents ages 6 to 17 years met primary endpoints on the ADHD-RS-5 and PERMP scales, with safety consistent with the broader methylphenidate class. Cingulate CEO Shane Schaffer called the response focused and resolvable.
White House Order Accelerates Psychedelic Research for Mental Illness, With Gus Alva, MD
A White House executive order signed April 18, 2026, directs the FDA and Drug Enforcement Administration to accelerate research and regulatory pathways for psychedelic drugs treating serious mental illness, including ibogaine compounds. The order authorizes national priority vouchers, Right to Try access, and ≥ $50 million in federal funding for state psychedelic research programs. Gus Alva, MD, medical director of ATP Clinical Research, told HCPLive that clinicians should treat patient questions about psychedelics as reflecting unmet treatment needs rather than dismiss them. Alva cautioned that therapist training and infrastructure must keep pace with policy change.
Phase 3 Pipeline: DT120 Delivers Rapid Relief in Major Depressive Disorder
Emerge Phase 3 Data Show DT120 Lysergide Delivers Rapid, Durable MDD Relief, Says John Sonnenberg, PhD
Definium Therapeutics reported positive phase 3 Emerge results for DT120 (lysergide) ODT 100 µg in major depressive disorder, meeting the primary endpoint and all key secondary endpoints. The multicenter, randomized, double-blind trial enrolled 149 adults across 20 sites, with a single dose producing an 8.1-point placebo-adjusted MADRS improvement at week 6 and 24% remission versus 3% on placebo.
Investigator John Sonnenberg, PhD, of Northwestern University Feinberg School of Medicine, said the data convinced him of psychedelics' genuine antidepressant efficacy. No serious adverse events or suicidality signals emerged, and Definium's second phase 3 study, Ascend, will add a low-dose arm.
Clinical Features: TMS Innovation and AI's Expanding Role in Psychiatry
TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know
Linda Carpenter, MD, of Brown University; Andrew Leuchter, MD, of UCLA TMS Clinical and Research Services; and Scott Wilke, MD, PhD, of UCLA Health, discussed how accelerated TMS protocols and the FDA-cleared at-home device ProlivRx are reshaping care for treatment-resistant depression. Standard TMS requires 36 sessions over 6 to 8 weeks, a schedule Medicare limits to 2 reimbursed sessions daily, leaving accelerated 5-or-more-session protocols largely uncovered. Carpenter, who led the MOOD trial behind ProlivRx (Neurolief), explained the physician-directed at-home model, while Wilke described how accelerated theta burst stimulation may target specific prefrontal cortex cell types.
Related:
Your Patient's New Therapist Is an AI. Now What?
As mental health care waitlists stretch 3 to 6 months, growing numbers of patients turn to AI chatbots like ChatGPT for support, raising concerns among psychiatrists.
Richard Miller, MD, of Elwyn Adult Behavioral Health, cautioned that AI-cherry-picked, decontextualized information can be deleterious rather than helpful. Bioethicist Dominic Sisti, PhD, from Penn Medicine, called for guardrails around age restrictions, suicide risk detection, and HIPAA compliance. Psychiatrist Darlene King, MD, of UT Southwestern, compared AI mental health advice to consulting a well-meaning but unreliable friend. Clinicians are encouraged to ask patients about AI use non-judgmentally and keep a human in the loop.
Advertisement
